Inactive Instrument

Roche Holding Ltd. Stock Swiss Exchange

Equities

CH0012032048

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Roche Holding Ltd.
Sales 2024 * 59.84B 65.55B Sales 2025 * 63.41B 69.46B Capitalization 177B 194B
Net income 2024 * 13.38B 14.65B Net income 2025 * 14.66B 16.05B EV / Sales 2024 * 3.19 x
Net Debt 2024 * 13.47B 14.75B Net Debt 2025 * 7.31B 8B EV / Sales 2025 * 2.91 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
11.9 x
Employees -
Yield 2024 *
4.36%
Yield 2025 *
4.54%
Free-Float 88.91%
More Fundamentals * Assessed data

Latest transcript on Roche Holding Ltd.

Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company